JPWO2019124488A1 - セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 - Google Patents

セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 Download PDF

Info

Publication number
JPWO2019124488A1
JPWO2019124488A1 JP2019560556A JP2019560556A JPWO2019124488A1 JP WO2019124488 A1 JPWO2019124488 A1 JP WO2019124488A1 JP 2019560556 A JP2019560556 A JP 2019560556A JP 2019560556 A JP2019560556 A JP 2019560556A JP WO2019124488 A1 JPWO2019124488 A1 JP WO2019124488A1
Authority
JP
Japan
Prior art keywords
sepetaprost
rho
combination
kinase inhibitor
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560556A
Other languages
English (en)
Japanese (ja)
Inventor
誉子 山元
誉子 山元
孝純 谷口
孝純 谷口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of JPWO2019124488A1 publication Critical patent/JPWO2019124488A1/ja
Priority to JP2023091268A priority Critical patent/JP2023110030A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019560556A 2017-12-21 2018-12-20 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 Pending JPWO2019124488A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023091268A JP2023110030A (ja) 2017-12-21 2023-06-02 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2017244847 2017-12-21
JP2017244847 2017-12-21
JP2018180658 2018-09-26
JP2018180658 2018-09-26
PCT/JP2018/046970 WO2019124488A1 (ja) 2017-12-21 2018-12-20 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023091268A Division JP2023110030A (ja) 2017-12-21 2023-06-02 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Publications (1)

Publication Number Publication Date
JPWO2019124488A1 true JPWO2019124488A1 (ja) 2020-12-17

Family

ID=66993448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560556A Pending JPWO2019124488A1 (ja) 2017-12-21 2018-12-20 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
JP2023091268A Pending JP2023110030A (ja) 2017-12-21 2023-06-02 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023091268A Pending JP2023110030A (ja) 2017-12-21 2023-06-02 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Country Status (9)

Country Link
US (2) US11446273B2 (https=)
EP (2) EP4338751B1 (https=)
JP (2) JPWO2019124488A1 (https=)
KR (1) KR102792934B1 (https=)
CN (1) CN111479568A (https=)
CA (1) CA3086457A1 (https=)
ES (2) ES2972934T3 (https=)
TW (2) TWI788484B (https=)
WO (1) WO2019124488A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
KR20230051199A (ko) * 2020-08-13 2023-04-17 산텐 세이야꾸 가부시키가이샤 세페타프로스트를 함유하는 의약 제제
TW202404569A (zh) 2022-04-22 2024-02-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之眼科用組合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107335A (ja) * 2002-08-29 2004-04-08 Santen Pharmaceut Co Ltd Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2011013651A1 (ja) * 2009-07-28 2011-02-03 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2012102357A1 (ja) * 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2012105674A1 (ja) * 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
DE3871596T3 (de) 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
CA2307285C (en) 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP4342704B2 (ja) 2000-07-21 2009-10-14 富士フイルム株式会社 液晶分子の配向方法
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4017921B2 (ja) 2002-06-12 2007-12-05 高砂熱学工業株式会社 暖房室内の空気循環装置
JP4128038B2 (ja) 2002-07-10 2008-07-30 富士フイルム株式会社 電子ペーパー
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2010113957A (ja) 2008-11-06 2010-05-20 Ntt Docomo Inc コネクタ
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP2011013651A (ja) 2009-07-03 2011-01-20 Mitsumasa Maeda フレキシブルディスプレイのれん
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107335A (ja) * 2002-08-29 2004-04-08 Santen Pharmaceut Co Ltd Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2011013651A1 (ja) * 2009-07-28 2011-02-03 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2012102357A1 (ja) * 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2012105674A1 (ja) * 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUBINER, HARVEY ET AL.: "Fixed dose combination of AR-13324 and latanoprost (PG324): A double-masked, randomized, controlled", INVEST. OPHTHALMOL. VIS. SCI., vol. 56, JPN6019010105, 2015, ISSN: 0005005877 *
ELLIS, EYDIE MILLER ET AL.: "Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day,", BR. J. OPHTHALMOL., vol. 101, JPN6019010115, 2016, pages 796 - 800, ISSN: 0005005881 *
LEWIS, RICHARD A ET AL.: "Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled", BR. J. OPHTHALMOL., vol. 100, JPN6019010108, 2016, pages 339 - 344, ISSN: 0005005878 *
TANIHARA, HIDENOBU ET AL.: "One-year clinical evaluation of 0.4% ripasudil(K-115) in patients with open-angle glaucoma andocular", ACTA OPHTHALMOLOGICA, vol. 94, JPN6019010111, 2016, pages 26 - 34, ISSN: 0005005879 *
YAMAGISHI, REIKO ET AL.: "IOP LOWING EFFECT OF SEPETAPROST ON MOUSE EYE", WORLD GLAUCOMA CONGRESS 7TH, JPN6019010113, June 2017 (2017-06-01), pages 534, ISSN: 0005005880 *
山岸麗子ほか: "新規 FP/EP3 dual 作動薬 sepetaprost のマウス眼圧に対する作用", 日本眼科学会雑誌, vol. 121, JPN6019010116, March 2017 (2017-03-01), pages 183 - 1, ISSN: 0005005882 *

Also Published As

Publication number Publication date
WO2019124488A1 (ja) 2019-06-27
EP4338751A2 (en) 2024-03-20
US11446273B2 (en) 2022-09-20
TW201927298A (zh) 2019-07-16
EP3730138A1 (en) 2020-10-28
EP3730138A4 (en) 2021-08-25
US20220387372A1 (en) 2022-12-08
CA3086457A1 (en) 2019-06-27
US20200316009A1 (en) 2020-10-08
EP4338751C0 (en) 2025-09-03
TWI833535B (zh) 2024-02-21
ES2972934T3 (es) 2024-06-17
KR20200103042A (ko) 2020-09-01
ES3041644T3 (en) 2025-11-13
EP4338751B1 (en) 2025-09-03
EP4338751A3 (en) 2024-05-22
EP3730138B1 (en) 2024-02-14
CN111479568A (zh) 2020-07-31
KR102792934B1 (ko) 2025-04-07
US12201602B2 (en) 2025-01-21
JP2023110030A (ja) 2023-08-08
TW202320747A (zh) 2023-06-01
TWI788484B (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
JP6383058B2 (ja) スルホンアミド化合物の組み合わせ
US12201602B2 (en) Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor
US9339496B2 (en) Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US20140018350A1 (en) Combination of sulfonamide compound and tafluprost
WO2019124489A1 (ja) セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
HK40102807B (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40102807A (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40029829A (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40024494A (en) MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND Rho-KINASE INHIBITOR
US20210106569A1 (en) Omidenepag combination
EA043888B1 (ru) Лекарственное средство, содержащее комбинацию сепетапроста и ингибитора rho-ассоциированной протеинкиназы, содержащей суперспираль
EA050493B1 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ КОМБИНАЦИЮ СЕПЕТАПРОСТА И ИНГИБИТОРА Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ
EA043474B1 (ru) Комбинация омиденепага
HK40029829B (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40025370A (en) Omidenepag combination
HK40029828A (en) Omidenepag combination

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307